REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Inc. reported its second quarter 2026 financial results, highlighting strong clinical execution and a solid cash runway. Key achievements include the AFFINITY DUCHENNE® trial meeting its primary endpoint, the initiation of the NAAVIGATE study for diabetic retinopathy, and FDA reaffirming the path forward …